Table 1.
Clinical and demographic characteristics of included subjects.
| Characteristic | Open Group, citalopram (n=26) |
Placebo- controlled Group, citalopram (n=20) |
Placebo- controlled Group, placebo (n=4) |
p Value |
|---|---|---|---|---|
|
| ||||
| Age (years) | 41.4 ± 12.0 | 45.7 ± 10.0 | 34.3 ± 10.2 | 0.140 |
|
| ||||
| Gender (% male) | 34.6 | 54.2 | 25.0 | 0.467 |
|
| ||||
| Ethnicity (% Hispanic) |
19.2 | 12.5 | 75.0 | 0.613 |
|
| ||||
| Race | 0.379 | |||
| % White | 50.0 | 66.7 | 75.0 | |
| % African- American |
29.2 | 25.0 | 0.0 | |
| % Other | 20.8 | 8.3 | 25.0 | |
|
| ||||
| Duration of current depressive episode (weeks) |
285.2 ± 459.8 | 155.1 ± 432.8 | 77.3 ± 69.6 | 0.525 |
|
| ||||
| Number of prior antidepressant medications |
1.3 ± 1.2 | 2.0 ± 2.0 | 1.3 ± 1.0 | 0.319 |
|
| ||||
| 24-item HRSD | 25.7 ± 5.5 | 26.1 ± 4.2 | 23.8 ± 2.8 | 0.679 |
|
| ||||
| QIDS SR | 19.7 ± 5.2 | 20.2 ± 7.3 | 17.8 ± 7.5 | 0.774 |
|
| ||||
| CGI-Severity | 4.4 ± 0.6 | 4.3 ± 0.5 | 4.3 ± 0.6 | 0.877 |
|
| ||||
| HARS | 13.2 ± 4.9 | 15.1 ± 4.8 | 16.7 ± 9.2 | 0.381 |
HRSD = Hamilton Rating Scale for Depression
QIDS SR = Quick Inventory of Depressive Symptomatology Self Report
CGI = Clinical Global Impressions
HARS = Hamilton Anxiety Rating Scale